September 30, 2021
An investor suit against biopharmaceutical company MacroGenics was dismissed on Wednesday by a Maryland federal judge who said the plaintiffs failed to show enough facts to support their claims of fraud and scienter.
September 16, 2019
Investors in a clinical-stage biopharmaceutical company have filed a proposed class action in Maryland federal court, accusing the drugmaker of falsely overstating the success of a breast cancer drug.